- Home
- CEAD vs RNAZ Comparison
CEAD vs RNAZ Comparison
Compare CEAD & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEAD
- RNAZ
- Stock Information
- Founded
- CEAD 2009
- RNAZ 2016
- Country
- CEAD United States
- RNAZ United States
- Employees
- CEAD N/A
- RNAZ N/A
- Industry
- CEAD Industrial Machinery/Components
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- CEAD Industrials
- RNAZ Health Care
- Exchange
- CEAD Nasdaq
- RNAZ Nasdaq
- Market Cap
- CEAD 4.7M
- RNAZ 4.9M
- IPO Year
- CEAD N/A
- RNAZ 2021
- Fundamental
- Price
- CEAD $8.24
- RNAZ $3.64
- Analyst Decision
- CEAD
- RNAZ Strong Buy
- Analyst Count
- CEAD 0
- RNAZ 1
- Target Price
- CEAD N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- CEAD 20.4K
- RNAZ 82.6K
- Earning Date
- CEAD 11-14-2024
- RNAZ 11-14-2024
- Dividend Yield
- CEAD N/A
- RNAZ N/A
- EPS Growth
- CEAD N/A
- RNAZ N/A
- EPS
- CEAD N/A
- RNAZ N/A
- Revenue
- CEAD $2,637,116.00
- RNAZ N/A
- Revenue This Year
- CEAD N/A
- RNAZ N/A
- Revenue Next Year
- CEAD N/A
- RNAZ $233.33
- P/E Ratio
- CEAD N/A
- RNAZ N/A
- Revenue Growth
- CEAD N/A
- RNAZ N/A
- 52 Week Low
- CEAD $5.60
- RNAZ $3.21
- 52 Week High
- CEAD $11.04
- RNAZ $264.00
- Technical
- Relative Strength Index (RSI)
- CEAD 65.10
- RNAZ 23.28
- Support Level
- CEAD $7.57
- RNAZ $3.21
- Resistance Level
- CEAD $8.49
- RNAZ $8.46
- Average True Range (ATR)
- CEAD 0.56
- RNAZ 0.74
- MACD
- CEAD 0.07
- RNAZ -0.27
- Stochastic Oscillator
- CEAD 89.88
- RNAZ 6.44
About CEAD CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.